These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22050317)

  • 21. Headache and symptoms of temporomandibular disorder: an epidemiological study.
    Gonçalves DA; Bigal ME; Jales LC; Camparis CM; Speciali JG
    Headache; 2010 Feb; 50(2):231-41. PubMed ID: 19751369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF).
    Leonardi M; Steiner TJ; Scher AT; Lipton RB
    J Headache Pain; 2005 Dec; 6(6):429-40. PubMed ID: 16388337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS).
    Blumenfeld AM; Varon SF; Wilcox TK; Buse DC; Kawata AK; Manack A; Goadsby PJ; Lipton RB
    Cephalalgia; 2011 Feb; 31(3):301-15. PubMed ID: 20813784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Sinus, Allergy and Migraine Study (SAMS).
    Eross E; Dodick D; Eross M
    Headache; 2007 Feb; 47(2):213-24. PubMed ID: 17300361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of cluster analysis to validate IHS diagnostic criteria for migraine and tension-type headache.
    Bruehl S; Lofland KR; Semenchuk EM; Rokicki LA; Penzien DB
    Headache; 1999 Mar; 39(3):181-9. PubMed ID: 15613212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid use and dependence among persons with migraine: results of the AMPP study.
    Buse DC; Pearlman SH; Reed ML; Serrano D; Ng-Mak DS; Lipton RB
    Headache; 2012 Jan; 52(1):18-36. PubMed ID: 22268775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The point prevalence of dizziness or vertigo in migraine--and factors that influence presentation.
    Calhoun AH; Ford S; Pruitt AP; Fisher KG
    Headache; 2011 Oct; 51(9):1388-92. PubMed ID: 21797862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of headache and migraine in Qatar.
    Bener A
    Neuroepidemiology; 2006; 27(2):61-6. PubMed ID: 16847389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population-based door-to-door survey of migraine in Japan: the Daisen study.
    Takeshima T; Ishizaki K; Fukuhara Y; Ijiri T; Kusumi M; Wakutani Y; Mori M; Kawashima M; Kowa H; Adachi Y; Urakami K; Nakashima K
    Headache; 2004 Jan; 44(1):8-19. PubMed ID: 14979878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres.
    Cevoli S; D'Amico D; Martelletti P; Valguarnera F; Del Bene E; De Simone R; Sarchielli P; Narbone M; Testa L; Genco S; Bussone G; Cortelli P
    Cephalalgia; 2009 Dec; 29(12):1285-93. PubMed ID: 19438916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden.
    Rozen TD; Fishman RS
    Headache; 2012 Jan; 52(1):99-113. PubMed ID: 22077141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis of migraine and tension-type headache: a population-based follow-up study.
    Lyngberg AC; Rasmussen BK; Jørgensen T; Jensen R
    Neurology; 2005 Aug; 65(4):580-5. PubMed ID: 16116119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic migraine, classification, differential diagnosis, and epidemiology.
    Lipton RB
    Headache; 2011; 51 Suppl 2():77-83. PubMed ID: 21770929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frovatriptan in the practice of office-based neurologists/pain therapists: Results of postmarketing surveillance study ALADIN.
    Wallasch TM
    Adv Ther; 2010 Jan; 27(1):56-62. PubMed ID: 20140543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The burden attributable to headache disorders in India: estimates from a community-based study in Karnataka State.
    Rao GN; Kulkarni GB; Gururaj G; Stovner LJ; Steiner TJ
    J Headache Pain; 2015; 16():94. PubMed ID: 26553066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin is first-line treatment for migraine and episodic tension-type headache regardless of headache intensity.
    Lampl C; Voelker M; Steiner TJ
    Headache; 2012 Jan; 52(1):48-56. PubMed ID: 21883198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
    Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
    Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantifying headache symptoms and other headache features from chart notes.
    Hasse LA; Ritchey PN; Smith R
    Headache; 2004 Oct; 44(9):873-84. PubMed ID: 15447696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.